Regenerative Peptides for Fibrosis Reduction via Sequence Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrosis are ineffective, and there is a need for anti-fibrotic therapies that can mimic the tissue regeneration capabilities of regenerative species.
Innovation Solution
Development of peptide compositions derived from regenerative species proteins, which are modified to improve cross-species homology, tissue penetration, stability, and affinity to human proteases, to regulate processes such as myofibroblast formation, bacterial infection, inflammation, and extracellular matrix production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide sequences are directly used from regenerative species without modification, then cross-species homology is maintained, but tissue penetration and peptide stability are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying peptide sequences through amino acid substitutions, deletions, or additions to improve stability and tissue penetration while maintaining functional homology. Specific modifications include adding cell-penetrating sequences and optimizing amino acid composition to enhance peptide performance without completely altering the regenerative function.
Solution Approach 2:
The patent introduces intermediary elements such as cell-penetrating sequences and linking peptides that mediate between the regenerative species peptide core and the human tissue environment. These intermediaries facilitate tissue penetration and stability without eliminating the underlying regenerative function of the original peptide sequence.
2Ease of operation
If peptide sequences are heavily modified to improve tissue penetration and stability, then therapeutic efficacy is enhanced, but affinity to human proteases and cross-species homology are reduced
Solution Approach 1:
The patent applies local quality by making targeted modifications at specific regions of the peptide sequence rather than uniform changes throughout. Cell-penetrating sequences are added at N- or C-termini, while critical functional regions are preserved to maintain protease affinity and cross-species homology. This localized approach allows optimization of specific properties without compromising others.
3Ease of manufacture
If current fibrosis treatments are used, then standard medical care is provided, but no effective reduction of fibrosis occurs
Solution Approach 1:
The patent applies copying by replicating the regenerative tissue repair mechanisms found in regenerative species (such as axolotl) and translating them into human-applicable peptide therapies. The core regenerative peptide sequences are copied and adapted to function in human systems, providing a novel mechanism that goes beyond current standard fibrosis treatments.
Data Source
AI summary
Provided herein are peptide compositions derived from regenerative species regenerative proteins, and methods of making and use thereof, that seek to reduce fibrosis. The disclosed peptide formulations and compositions may be used to reduce fibrosis resulting from any disease or disorder, e.g., fibrosis associated with tissue inflammation, wounds, disease, or infection.